Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture. The expression system, polynucleotides, proteins, cells, and pharmaceutical compositions are useful in the prophylaxis or treatment of infections. The invention further relates to nucleotide constructs which comprises, essentially consists or consists of a polynucleotide encoding a modified influenza hemagglutinin (HA).

Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Abstract: The present invention relates to CD81-binding peptides of the hepatitis virus C(HCV) E2 glycoprotein, which are devoid of or mutated within the amino-terminal 27 amino acids of the mature E2 envelope glycoprotein, or variant thereof which retains the ability to bind to CD81. Furthermore, the present invention provides polypeptides comprising said CD81-binding peptide, polynucleotides encoding the CD81-binding peptide, and expression cassettes and vectors comprising the polynucleotide of the invention. Moreover, the present invention relates to compositions comprising the CD81-binding peptide, the polynucleotide encoding the CD81-binding peptide, the expression cassette, or the vector, and an adjuvant. Furthermore, the present invention provides a pharmaceutical composition comprising the CD81-binding peptide, the polynucleotide, the expression cassette, the vector, or the composition of the invention, and a pharmaceutically acceptable excipient, carrier, or diluent.